Obesity and diabetes will bury our country if we don’t stem the onslaught of this double whammy. Proposed solutions abound but must be tested and cleared for general use. The FDA’s role as the arbiter that decides whether companies may or may not market their products depends on clinical trials and rigorous investigations. Any approach that could stem obesity or diabetes is trial-worthy because the combined threat is so dire it cannot be waved off. Dismissive gestures can be relevant, however.
The University of Virginia’s (UVA) Center for Diabetes Technology (CDT) recently announced a new study to investigate gestures, dismissive and otherwise, as potential weapons in the war against diabetes and obesity. UVA licensed Klue’s gesture detection software for a 12-week clinical trial.
In 2017 we wrote about Klue, Inc.’s AI-powered wearable software that detects user hand gestures related to eating and drinking. Based on personalized data gathered over time, the app acts as a wellness coach, informing and prompting users to change behavior related to unhealthy eating.
We’re interested in the outcome of this investigation particularly because it is noninvasive, passive, and does not involve drugs or surgery. The CDT is currently enrolling people with type 1 diabetes for the Klue study. We will report on the results and reports from the clinical trial when they are published.
